Published online Aug 27, 2025. doi: 10.4240/wjgs.v17.i8.106860
Revised: March 30, 2025
Accepted: April 22, 2025
Published online: August 27, 2025
Processing time: 169 Days and 1.5 Hours
This article discusses the original article published by Lu et al in the latest issue. The article confirmed through a cohort study the clinical efficacy of the triple live bacteria of Bifidobacterium combined with mirtazapine in treating postoperative depression of gastric cancer patients, also explored the multi-target therapeutic mechanisms of Bifidobacterium triple viable bacteria combined with mirtazapine in managing depression in patients after radical gastrectomy for gastric cancer for the first time. The results indicated that Bifidobacterium could alleviate depression in patients after radical gastrectomy for gastric cancer. Gastric cancer patients undergoing surgery frequently experience postoperative psychological disorders, notably depression. These conditions not only impair quality of life but also negatively impact disease-free and overall survival. This editorial explores the underestimated psychological challenges following gastric cancer surgery, including depression, anxiety, ad
Core Tip: Postoperative depression in gastric cancer patients significantly influences recovery, which links to reduced survival. Bifidobacterium triple viable probiotics, alongside mirtazapine, offer a multifaceted treatment strategy by restoring gut microbiota, modulating immunity, and regulating the microbiota-gut-brain axis to alleviate depression. Beyond mental health, these probiotics enhance gastrointestinal function, immunity, and nutrition, supporting comprehensive postoperative recovery. Personalized regimens based on gut microbiota profiles could further improve outcomes, to achieve the greatest possible improvement in the depression status of patients after gastric cancer surgery.